Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma.

Antineoplastic Combined Chemotherapy Protocols / therapeutic use Cyclophosphamide / therapeutic use Disease-Free Survival Doxorubicin / therapeutic use Humans Lymphoma, Large B-Cell, Diffuse / diagnosis Muscles Prednisone / therapeutic use Prognosis Retrospective Studies Rituximab / therapeutic use Vincristine / therapeutic use
Muscle mass diffuse large B-cell lymphoma muscle density overall survival sarcopenia

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
07 2020
Historique:
pubmed: 14 3 2020
medline: 28 4 2021
entrez: 14 3 2020
Statut: ppublish

Résumé

Low muscle mass (LMM) and low muscle density (LMD) are increasingly recognized as prognostic factors for survival in different malignancies. This study determined the association of LMM and LMD with survival in DLBCL (diffuse large B-cell lymphoma) patients. CT-based measurement of muscle was performed in 164 DLBCL patients prior to chemo-immunotherapy.

Identifiants

DOI: 10.1080/10428194.2020.1737686 PMID: 32167390
pubmed: 32167390
doi: 10.1080/10428194.2020.1737686
doi:

Substances chimiques

Rituximab 4F4X42SYQ6
Vincristine 5J49Q6B70F
Doxorubicin 80168379AG
Cyclophosphamide 8N3DW7272P
Prednisone VB0R961HZT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1618-1626

Auteurs

Hánah N Rier (HN)

Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.

Hardjit Kharagjitsing (H)

Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.

Joost van Rosmalen (J)

Department of Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands.

Jla van Vugt (J)

Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands.

Peter E Westerweel (PE)

Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
ORCID: 0000-0002-0746-7039

Eva de Jongh (E)

Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.

Mark Kock (M)

Department of Radiology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.

Mark-David Levin (MD)

Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Prognostic impact of low muscle mass and low...
questionsmedicales.fr › Composés chimiques organiques › Composés organiques du phosphore › Phosphoramides › Moutardes phosphoramide › Cyclophosphamide › Prognostic impact of low muscle mass and low...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans rechute › Prognostic impact of low muscle mass and low...
questionsmedicales.fr › Glucides › Hétérosides › Aminosides › Anthracyclines › Daunorubicine › Doxorubicine › Prognostic impact of low muscle mass and low...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Prognostic impact of low muscle mass and low...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome B › Lymphome B diffus à grandes cellules › Prognostic impact of low muscle mass and low...
questionsmedicales.fr › Tissus › Muscles › Prognostic impact of low muscle mass and low...
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Prégnanes › Prégnadiènes › Prégnadiènediols › Prednisone › Prognostic impact of low muscle mass and low...
questionsmedicales.fr › Diagnostic › Pronostic › Prognostic impact of low muscle mass and low...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Prognostic impact of low muscle mass and low...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux d'origine murine › Rituximab › Prognostic impact of low muscle mass and low...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Indolizine › Indolizidines › Alcaloïdes indoliques › Alcaloïdes formés par condensation de sécologanine et de tryptamine › Alcaloïdes de Vinca › Vincristine › Prognostic impact of low muscle mass and low...